Abstract
Background Antinuclear antibodies (ANA) and extractable nuclear antigens (ENA) are crucial biomarkers for the diagnosis of autoimmune diseases (AID) such as systemic lupus erythematosus (SLE), Sjogren’s syndrome, systemic sclerosis, and polymyositis. In the present study, we assessed the most frequent ANA patterns associated with the most detectable ENA antigen (Ag) that could be used as a diagnostic and efficient prognostic marker of AID.
Materials and Methods The primary objective of this study was to investigate the association between immunofluorescence (IF) ANA and ENA in patients with AIDs. This was a retrospective cross-sectional study. The study was performed at the Immunology Department of the Armed Forces Institute of Pathology, Rawalpindi. Retrospective data from 76 patients were tested for ANA and ENA from June 2020 to Nov 2020.
Results A total of 76 patients comprising 14 (18.4%) males and 62(81.6%) females were tested for AIDs. The most frequent pattern among AID patients was coarse speckled, followed by the peripheral ANA pattern. The most frequent ENA Ags were Sjogren’s syndrome A (SSA) and B (SSB). SSA was significantly associated with coarse speckled and peripheral ANA patterns, whereas SSB was associated with coarse speckled ANA patterns. These associations are relevant for accurate diagnosis of autoimmune diseases.
Conclusion SSA was associated with coarse speckled and peripheral ANA patterns, whereas SSB was associated with coarse speckled ANA patterns. The ANA patterns were significantly associated with ENA antigens.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Armed Forces Institute of Pathology, Combined Military Hospital, Rawalpindi gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
